董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Scheller | 男 | Director | 66 | 未披露 | 未持股 | 2020-04-24 |
| Carl Gordon | 男 | Director | 55 | 未披露 | 未持股 | 2020-04-24 |
| Richard Heyman | 男 | Chairman and Director | 62 | 未披露 | 未持股 | 2020-04-24 |
| Jacob M. Chacko | 男 | President, Chief Executive Officer and Director | 41 | 67.21万美元 | 未持股 | 2020-04-24 |
| Mardi Dier | 女 | Director | 58 | 未披露 | 未持股 | 2020-04-24 |
| Leo Guthart | 男 | Director | 82 | 未披露 | 未持股 | 2020-04-24 |
| Richard Heyman | 男 | Chairman and Director | 63 | 7.50万美元 | 未持股 | 2020-04-24 |
| Peter Svennilson | 男 | Director | 58 | 未披露 | 未持股 | 2020-04-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Pratik Multani | 男 | Chief Medical Officer | 53 | 53.52万美元 | 未持股 | 2020-04-24 |
| Jacob M. Chacko | 男 | President, Chief Executive Officer and Director | 41 | 67.21万美元 | 未持股 | 2020-04-24 |
| Dominic Piscitelli | 男 | Chief Financial Officer | 45 | 123.67万美元 | 未持股 | 2020-04-24 |
董事简历
中英对照 | 中文 | 英文- Richard Scheller
-
Richard Scheller，自2019年6月起担任Maze Therapeutics，Inc.董事会成员。Scheller博士目前担任生物技术公司BridgeBio Pharma Inc.的研发主席，自2019年1月起担任该职务，并于2018年1月至2021年2月担任该公司董事会成员。他此前曾于2015年至2019年担任个人基因组学公司23andMe，Inc.的Therapeutics负责人和首席科学官，并自2019年初起担任该公司董事会成员。他还担任Alector, Inc.的董事会成员。从2001年到2014年，Scheller博士在生物技术公司基因泰克工作了14年，在那里他担任研究和早期开发执行副总裁。1982年至2001年，谢勒博士在斯坦福大学任教，担任生物科学系和分子与细胞生理学系教授，并担任斯坦福大学医学中心霍华德·休斯医学研究所的研究员。自2004年以来，Scheller博士一直担任加州大学旧金山分校生物化学和生物物理系的兼职教授。他在职业生涯中发表了200多篇初级研究论文。Scheller博士获得Kavli神经科学奖（2010年），是美国国家科学院和美国国家医学研究院的成员。Scheller博士获得了加州理工学院的化学博士学位和威斯康星大学麦迪逊分校的生物化学学士学位。
Richard Scheller,has served as a member of Board of Directors and Scientific Advisory Board ("SAB") since October 2018 and has served as co-chair of Strategic Portfolio Advice and Review Committee ("SPARC") since December 2019. Dr. Scheller has served as the Chairman of Research and Development at BridgeBio Pharma LLC, a publicly traded biotechnology company, since January 2019 and as a member of its board of directors from 2018 to 2023. In addition, Dr. Scheller serves on the board of directors at Maze Therapeutics, Aarvik Therapeutics, Trace Neuroscience, Xaira, and GondolaBio, and on the board of trustees at Caltech and the board of the Corporation of the Fine Arts Museums of San Francisco. He previously served on the board of directors of Xenon Pharmaceuticals from 2015 to 2020, ORIC Pharmaceuticals from 2015 to 2021, and as chairman of the board of directors of DICE Therapeutics from 2015 to 2023. From 2015 to 2019, Dr. Scheller was Head of Therapeutics and Chief Scientific Officer at 23andMe Holding Co. At Genentech from 2001 to 2014, he was Executive Vice President of Research and Early Development and served on the executive committees of Roche and Genentech focusing on research strategy, drug discovery, business development and early drug development activities. From 1982 to 2001, Dr. Scheller was a professor at Stanford in the Department of Biological Sciences and the Department of Molecular and Cellular Physiology and was an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center. Since 2004, Dr. Scheller has served as an adjunct professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco. Dr. Scheller's research elucidating the molecular machinery and regulatory mechanism that underly neurotransmitter release earned him the 2013 Albert Lasker Basic Medical Research Award, the 2010 Kavli Prize in Neuroscience, and the 1997 U.S. National Academy of Sciences Award in Molecular Biology. He is a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences, and a member of the National Academy of Medicine. Dr. Scheller holds a Ph.D. in Chemistry from the California Institute of Technology and B.Sc. in Biochemistry from the University of Wisconsin-Madison. - Richard Scheller，自2019年6月起担任Maze Therapeutics，Inc.董事会成员。Scheller博士目前担任生物技术公司BridgeBio Pharma Inc.的研发主席，自2019年1月起担任该职务，并于2018年1月至2021年2月担任该公司董事会成员。他此前曾于2015年至2019年担任个人基因组学公司23andMe，Inc.的Therapeutics负责人和首席科学官，并自2019年初起担任该公司董事会成员。他还担任Alector, Inc.的董事会成员。从2001年到2014年，Scheller博士在生物技术公司基因泰克工作了14年，在那里他担任研究和早期开发执行副总裁。1982年至2001年，谢勒博士在斯坦福大学任教，担任生物科学系和分子与细胞生理学系教授，并担任斯坦福大学医学中心霍华德·休斯医学研究所的研究员。自2004年以来，Scheller博士一直担任加州大学旧金山分校生物化学和生物物理系的兼职教授。他在职业生涯中发表了200多篇初级研究论文。Scheller博士获得Kavli神经科学奖（2010年），是美国国家科学院和美国国家医学研究院的成员。Scheller博士获得了加州理工学院的化学博士学位和威斯康星大学麦迪逊分校的生物化学学士学位。
- Richard Scheller,has served as a member of Board of Directors and Scientific Advisory Board ("SAB") since October 2018 and has served as co-chair of Strategic Portfolio Advice and Review Committee ("SPARC") since December 2019. Dr. Scheller has served as the Chairman of Research and Development at BridgeBio Pharma LLC, a publicly traded biotechnology company, since January 2019 and as a member of its board of directors from 2018 to 2023. In addition, Dr. Scheller serves on the board of directors at Maze Therapeutics, Aarvik Therapeutics, Trace Neuroscience, Xaira, and GondolaBio, and on the board of trustees at Caltech and the board of the Corporation of the Fine Arts Museums of San Francisco. He previously served on the board of directors of Xenon Pharmaceuticals from 2015 to 2020, ORIC Pharmaceuticals from 2015 to 2021, and as chairman of the board of directors of DICE Therapeutics from 2015 to 2023. From 2015 to 2019, Dr. Scheller was Head of Therapeutics and Chief Scientific Officer at 23andMe Holding Co. At Genentech from 2001 to 2014, he was Executive Vice President of Research and Early Development and served on the executive committees of Roche and Genentech focusing on research strategy, drug discovery, business development and early drug development activities. From 1982 to 2001, Dr. Scheller was a professor at Stanford in the Department of Biological Sciences and the Department of Molecular and Cellular Physiology and was an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center. Since 2004, Dr. Scheller has served as an adjunct professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco. Dr. Scheller's research elucidating the molecular machinery and regulatory mechanism that underly neurotransmitter release earned him the 2013 Albert Lasker Basic Medical Research Award, the 2010 Kavli Prize in Neuroscience, and the 1997 U.S. National Academy of Sciences Award in Molecular Biology. He is a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences, and a member of the National Academy of Medicine. Dr. Scheller holds a Ph.D. in Chemistry from the California Institute of Technology and B.Sc. in Biochemistry from the University of Wisconsin-Madison.
- Carl Gordon
-
Carl Gordon，自2020年7月起担任Mbx Biosciences, Inc.董事会成员。他曾担任OrbiMed Advisors LLC（一家投资公司）的创始成员、管理合伙人和全球私募股权联席主管（1998年以来）。他目前担任Adicet Bio, Inc.（纳斯达克代码：ACET）， ArriVent Biopharma Inc.（纳斯达克代码：AVBP）， Compass Therapeutics, Inc.（纳斯达克代码：CMPX）， Keros Therapeutics, Inc.（纳斯达克代码：KROS）和Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN）以及几家私人公司的董事会成员。他曾任职于Alector, Inc.（纳斯达克代码：ALEC）， Gemini Therapeutics, Inc.（前纳斯达克代码：GMTX，与Disc Medicine, Inc.合并），Kinnate Biopharma Inc.（纳斯达克代码：KNTE）， ORIC Pharmaceuticals, Inc.（纳斯达克代码：ORIC）， Passage Bio, Inc.（纳斯达克代码：PASG）， precintics Inc.（前纳斯达克代码：PRVL，被Eli Lilly收购），SpringWorks Therapeutics, Inc.（纳斯达克代码：SWTX）， Theseus Pharmaceuticals, Inc.（前纳斯达克代码：SWTX）的董事会。THRX（被Concentra Biosciences LLC收购）和Turning Point Therapeutics, Inc.（前纳斯达克股票代码：TPTX，被Bristol Myers Squibb Co.收购）。他持有Harvard College的化学学士学位，Massachusetts Institute of Technology的分子生物学博士学位，也是the Rockefeller University的研究员。
Carl Gordon,has served on Mbx Biosciences, Inc. board of directors since July 2020. He has served as a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm, since 1998. Dr. Gordon currently serves on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET), ArriVent Biopharma Inc. (Nasdaq: AVBP), Compass Therapeutics, Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS), and Terns Pharmaceuticals, Inc. (Nasdaq: TERN), as well as several private companies. Dr. Gordon previously served on the boards of Alector, Inc. (Nasdaq: ALEC), Gemini Therapeutics, Inc. (formerly Nasdaq: GMTX which merged with Disc Medicine, Inc.), Kinnate Biopharma Inc. (Nasdaq: KNTE), ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), Passage Bio, Inc. (Nasdaq: PASG), Prevail Therapeutics Inc. (formerly Nasdaq: PRVL which was acquired by Eli Lilly), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), Theseus Pharmaceuticals, Inc. (formerly Nasdaq: THRX which was acquired by Concentra Biosciences LLC), and Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX which was acquired by Bristol Myers Squibb Co.). Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University. - Carl Gordon，自2020年7月起担任Mbx Biosciences, Inc.董事会成员。他曾担任OrbiMed Advisors LLC（一家投资公司）的创始成员、管理合伙人和全球私募股权联席主管（1998年以来）。他目前担任Adicet Bio, Inc.（纳斯达克代码：ACET）， ArriVent Biopharma Inc.（纳斯达克代码：AVBP）， Compass Therapeutics, Inc.（纳斯达克代码：CMPX）， Keros Therapeutics, Inc.（纳斯达克代码：KROS）和Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN）以及几家私人公司的董事会成员。他曾任职于Alector, Inc.（纳斯达克代码：ALEC）， Gemini Therapeutics, Inc.（前纳斯达克代码：GMTX，与Disc Medicine, Inc.合并），Kinnate Biopharma Inc.（纳斯达克代码：KNTE）， ORIC Pharmaceuticals, Inc.（纳斯达克代码：ORIC）， Passage Bio, Inc.（纳斯达克代码：PASG）， precintics Inc.（前纳斯达克代码：PRVL，被Eli Lilly收购），SpringWorks Therapeutics, Inc.（纳斯达克代码：SWTX）， Theseus Pharmaceuticals, Inc.（前纳斯达克代码：SWTX）的董事会。THRX（被Concentra Biosciences LLC收购）和Turning Point Therapeutics, Inc.（前纳斯达克股票代码：TPTX，被Bristol Myers Squibb Co.收购）。他持有Harvard College的化学学士学位，Massachusetts Institute of Technology的分子生物学博士学位，也是the Rockefeller University的研究员。
- Carl Gordon,has served on Mbx Biosciences, Inc. board of directors since July 2020. He has served as a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm, since 1998. Dr. Gordon currently serves on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET), ArriVent Biopharma Inc. (Nasdaq: AVBP), Compass Therapeutics, Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS), and Terns Pharmaceuticals, Inc. (Nasdaq: TERN), as well as several private companies. Dr. Gordon previously served on the boards of Alector, Inc. (Nasdaq: ALEC), Gemini Therapeutics, Inc. (formerly Nasdaq: GMTX which merged with Disc Medicine, Inc.), Kinnate Biopharma Inc. (Nasdaq: KNTE), ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), Passage Bio, Inc. (Nasdaq: PASG), Prevail Therapeutics Inc. (formerly Nasdaq: PRVL which was acquired by Eli Lilly), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), Theseus Pharmaceuticals, Inc. (formerly Nasdaq: THRX which was acquired by Concentra Biosciences LLC), and Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX which was acquired by Bristol Myers Squibb Co.). Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.
- Richard Heyman
-
暂无中文简介
Richard Heyman has served as a member of our board of directors since March 2015 and as Chairman of our board of directors since May 2018. Dr. Heyman also served as our President and Chief Executive Officer from November 2015 to May 2016 and as our Acting President and Chief Executive Officer from November 2017 to May 2018. Since June 2015 he has served as the Executive Chairman and Co-Founder of Metacrine, Inc., a private biotechnology company. Since 2019 Dr. Heyman has also served as a venture partner for Arch Ventures, a venture capital firm. From August 2013 to April 2015 Dr. Heyman served as President and Chief Executive Officer of Seragon, which was acquired by Genentech in 2014. Prior to that, he served as Co-Founder, President and Chief Executive Officer of Aragon Pharmaceuticals, Inc., a biotechnology company that was acquired by Johnson & Johnson, a medical device, pharmaceutical and consumer packaged goods company, in 2013. Dr. Heyman currently serves on the board of directors of Gritstone Oncology, Inc., an oncology company. He is Vice Chair of the Board of Trustees at the Salk Institute, on the Board Foundation for the American Association for Cancer Research and on the executive committee at the University of California at San Diego Moores Cancer Center. Dr. Heyman received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut. -
暂无中文简介
- Richard Heyman has served as a member of our board of directors since March 2015 and as Chairman of our board of directors since May 2018. Dr. Heyman also served as our President and Chief Executive Officer from November 2015 to May 2016 and as our Acting President and Chief Executive Officer from November 2017 to May 2018. Since June 2015 he has served as the Executive Chairman and Co-Founder of Metacrine, Inc., a private biotechnology company. Since 2019 Dr. Heyman has also served as a venture partner for Arch Ventures, a venture capital firm. From August 2013 to April 2015 Dr. Heyman served as President and Chief Executive Officer of Seragon, which was acquired by Genentech in 2014. Prior to that, he served as Co-Founder, President and Chief Executive Officer of Aragon Pharmaceuticals, Inc., a biotechnology company that was acquired by Johnson & Johnson, a medical device, pharmaceutical and consumer packaged goods company, in 2013. Dr. Heyman currently serves on the board of directors of Gritstone Oncology, Inc., an oncology company. He is Vice Chair of the Board of Trustees at the Salk Institute, on the Board Foundation for the American Association for Cancer Research and on the executive committee at the University of California at San Diego Moores Cancer Center. Dr. Heyman received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.
- Jacob M. Chacko
-
JacobM.Chacko自2018年5月起担任我们的首席执行官兼董事会成员，自2019年5月起担任我们的总裁。2014年5月至2018年2月，他担任精密肿瘤公司Ignyta，Inc.的首席财务官，该公司于2018年2月被制药和诊断公司Roche Holding AG收购。2008年8月至2014年5月，Chacko博士担任私募股权投资公司TPG Capital的Vice President。在此之前，Chacko博士是麦肯锡公司（McKinsey&Company）梦百合客户的顾问，这是一家管理咨询公司。他目前任职于制药公司Turning PointTherapeutics，Inc.和制药公司4DMolecularTherapeutics，Inc.的董事会。Chacko博士在加州大学洛杉矶分校（UCLA）获得工商管理硕士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。从牛津大学获得生物学学士学位，从南加州大学获得老年学学士学位。
Jacob M. Chacko has served as our Chief Executive Officer and as a member of our board of directors since May 2018 and as our President since May 2019. From May 2014 to February 2018 he served as Chief Financial Officer of Ignyta, Inc., a precision oncology company that was acquired in February 2018 by Roche Holding AG, a pharmaceuticals and diagnostics company. From August 2008 to May 2014 Dr. Chacko served as Vice President at TPG Capital, a private equity investment firm. Prior to that, Dr. Chacko was a consultant to healthcare clients at McKinsey & Company, a management consulting firm. He currently serves on the board of directors of Turning Point Therapeutics, Inc., a pharmaceutical company, and 4D Molecular Therapeutics, Inc., a pharmaceutical company. Dr. Chacko received an M.D. from UCLA, an M.B.A. from Harvard Business School, an M.Sc. from Oxford University and a B.A. in biology and B.S. in gerontology from the University of Southern California. - JacobM.Chacko自2018年5月起担任我们的首席执行官兼董事会成员，自2019年5月起担任我们的总裁。2014年5月至2018年2月，他担任精密肿瘤公司Ignyta，Inc.的首席财务官，该公司于2018年2月被制药和诊断公司Roche Holding AG收购。2008年8月至2014年5月，Chacko博士担任私募股权投资公司TPG Capital的Vice President。在此之前，Chacko博士是麦肯锡公司（McKinsey&Company）梦百合客户的顾问，这是一家管理咨询公司。他目前任职于制药公司Turning PointTherapeutics，Inc.和制药公司4DMolecularTherapeutics，Inc.的董事会。Chacko博士在加州大学洛杉矶分校（UCLA）获得工商管理硕士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。从牛津大学获得生物学学士学位，从南加州大学获得老年学学士学位。
- Jacob M. Chacko has served as our Chief Executive Officer and as a member of our board of directors since May 2018 and as our President since May 2019. From May 2014 to February 2018 he served as Chief Financial Officer of Ignyta, Inc., a precision oncology company that was acquired in February 2018 by Roche Holding AG, a pharmaceuticals and diagnostics company. From August 2008 to May 2014 Dr. Chacko served as Vice President at TPG Capital, a private equity investment firm. Prior to that, Dr. Chacko was a consultant to healthcare clients at McKinsey & Company, a management consulting firm. He currently serves on the board of directors of Turning Point Therapeutics, Inc., a pharmaceutical company, and 4D Molecular Therapeutics, Inc., a pharmaceutical company. Dr. Chacko received an M.D. from UCLA, an M.B.A. from Harvard Business School, an M.Sc. from Oxford University and a B.A. in biology and B.S. in gerontology from the University of Southern California.
- Mardi Dier
-
Mardi Dier自2020年2月以来一直担任我们的董事会成员。Dier女士自2013年11月起担任Portola Pharmaceuticals执行Vice President兼首席财务官，自2018年10月起担任首席商务官，并于2006年8月至2013年11月担任高级副总裁兼首席财务官。Dier从2003年到2006年担任Chiron Corporation（一家生物制药公司）投资者关系Vice President。Dier从1994年到2001年担任Prudential Securities，Inc.（一家证券公司）投资银行董事。Dier女士之前从1986年到1990年担任毕马威会计师事务所（KPMG Peat Marwick）审计部的监督高级会计师。自2017年10月以来，迪尔女士一直担任生物制药公司AdamasPharmaceuticals，Inc.的董事兼审计委员会成员。Dier女士拥有斯坦福大学（Stanford University）生物学学士学位和加州大学洛杉矶分校安德森管理研究生院（Anderson Graduate School of Management）工商管理硕士学位。
Mardi Dier has served as a member of our board of directors since February 2020. Ms. Dier has served as Executive Vice President and Chief Financial Officer of Portola Pharmaceuticals since November 2013 as its Chief Business Officer since October 2018 and as a Senior Vice President and Chief Financial Officer from August 2006 to November 2013. From 2003 to 2006 Ms. Dier served as Vice President of Investor Relations at Chiron Corporation, a biopharmaceutical company. From 1994 to 2001 Ms. Dier served as a Director, Investment Banking at Prudential Securities, Inc., a securities firm. Ms. Dier previously served as a supervising senior accountant at the audit department of KPMG Peat Marwick, an accounting firm, from 1986 to 1990. Since October 2017 Ms. Dier has served as a Director, and member of the audit committee, of Adamas Pharmaceuticals, Inc., a biopharmaceutical company. Ms. Dier holds a B.S. in Biology from Stanford University and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles. - Mardi Dier自2020年2月以来一直担任我们的董事会成员。Dier女士自2013年11月起担任Portola Pharmaceuticals执行Vice President兼首席财务官，自2018年10月起担任首席商务官，并于2006年8月至2013年11月担任高级副总裁兼首席财务官。Dier从2003年到2006年担任Chiron Corporation（一家生物制药公司）投资者关系Vice President。Dier从1994年到2001年担任Prudential Securities，Inc.（一家证券公司）投资银行董事。Dier女士之前从1986年到1990年担任毕马威会计师事务所（KPMG Peat Marwick）审计部的监督高级会计师。自2017年10月以来，迪尔女士一直担任生物制药公司AdamasPharmaceuticals，Inc.的董事兼审计委员会成员。Dier女士拥有斯坦福大学（Stanford University）生物学学士学位和加州大学洛杉矶分校安德森管理研究生院（Anderson Graduate School of Management）工商管理硕士学位。
- Mardi Dier has served as a member of our board of directors since February 2020. Ms. Dier has served as Executive Vice President and Chief Financial Officer of Portola Pharmaceuticals since November 2013 as its Chief Business Officer since October 2018 and as a Senior Vice President and Chief Financial Officer from August 2006 to November 2013. From 2003 to 2006 Ms. Dier served as Vice President of Investor Relations at Chiron Corporation, a biopharmaceutical company. From 1994 to 2001 Ms. Dier served as a Director, Investment Banking at Prudential Securities, Inc., a securities firm. Ms. Dier previously served as a supervising senior accountant at the audit department of KPMG Peat Marwick, an accounting firm, from 1986 to 1990. Since October 2017 Ms. Dier has served as a Director, and member of the audit committee, of Adamas Pharmaceuticals, Inc., a biopharmaceutical company. Ms. Dier holds a B.S. in Biology from Stanford University and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.
- Leo Guthart
-
Leo Guthart于2015年11月至2020年4月担任我们的董事会成员。2000年以来，他曾一直担任Topspin公司（风险投资基金）的创始人，目前担任其管理合伙人。在此之前，Guthart博士担任Pittway Corporation（一家安全公司）安全组的董事长兼首席执行官。Guthart博士在包装供应公司AptarGroup Inc.的董事会任职至2015年。Guthart博士在哈佛商学院（Harvard Business School）获得D.B.A和M.B.A.，并在哈佛学院（Harvard College）获得物理学学士学位。
Leo Guthart served as a member of our board of directors from November 2015 until April 2020. Since 2000 he has served as a founder of Topspin, a venture capital fund, and currently serves as its Managing Partner. Prior to that, Dr. Guthart served as Chairman and Chief Executive Officer of the security group of Pittway Corporation, a security company. Dr. Guthart served on the board of directors of AptarGroup Inc., a packaging supply company until 2015. Dr. Guthart received a D.B.A and M.B.A. from Harvard Business School and a B.A. in physics from Harvard College. - Leo Guthart于2015年11月至2020年4月担任我们的董事会成员。2000年以来，他曾一直担任Topspin公司（风险投资基金）的创始人，目前担任其管理合伙人。在此之前，Guthart博士担任Pittway Corporation（一家安全公司）安全组的董事长兼首席执行官。Guthart博士在包装供应公司AptarGroup Inc.的董事会任职至2015年。Guthart博士在哈佛商学院（Harvard Business School）获得D.B.A和M.B.A.，并在哈佛学院（Harvard College）获得物理学学士学位。
- Leo Guthart served as a member of our board of directors from November 2015 until April 2020. Since 2000 he has served as a founder of Topspin, a venture capital fund, and currently serves as its Managing Partner. Prior to that, Dr. Guthart served as Chairman and Chief Executive Officer of the security group of Pittway Corporation, a security company. Dr. Guthart served on the board of directors of AptarGroup Inc., a packaging supply company until 2015. Dr. Guthart received a D.B.A and M.B.A. from Harvard Business School and a B.A. in physics from Harvard College.
- Richard Heyman
-
Richard Heyman，自2022年12月起担任Rayzebio，Inc.董事会成员和Rayzebio，Inc.董事会主席。Heyman博士是ORIC制药公司、Enliven治疗公司和PMV制药公司的董事会成员。Heyman博士是Metacrine公司的联合创始人，2015年6月至2023年3月担任该公司董事会主席，2015年10月至2016年6月担任该公司临时首席执行官。Heyman博士曾于2015年11月至2022年8月担任生物技术公司Gritstone Oncology的董事会成员，并于2016年5月至2022年6月担任生物技术公司Yumanity的董事会成员。从2013年8月至2015年4月，海曼博士担任私营生物技术公司Seragon Pharmaceuticals，Inc.的首席执行官，该公司于2014年8月被基因泰克收购。在加入Seragon之前，Heyman博士是Aragon Pharmaceuticals，Inc.的联合创始人和首席执行官，直到2013年8月被强生收购。他是索尔克生物研究所董事会副主席，AACR董事会基金会副主席，加州大学圣迭戈摩尔斯癌症中心访客委员会副主席。Heyman博士在明尼苏达大学获得药理学博士学位，在康涅狄格大学获得化学学士学位。
Richard Heyman,has served as a member of Rayzebio, Inc. board of directors and as Chairman of Rayzebio, Inc. board of directors since December 2022. Dr. Heyman serves as a member of the boards of directors of ORIC Pharmaceuticals, Inc., Enliven Therapeutics, Inc. and PMV Pharmaceuticals, Inc. Dr. Heyman was the co-founder of Metacrine, Inc. and served as the Chairman of its board of directors from June 2015 to March 2023 and was a co-founder of ORIC Pharmaceuticals, Inc. and served as its interim chief executive officer from October 2015 until June 2016. Dr. Heyman previously served as a member of the board of directors of Gritstone Oncology, a biotechnology company, from November 2015 to August 2022 and Yumanity, a biotechnology company, from May 2016 to June 2022. From August 2013 until April 2015, Dr. Heyman served as the chief executive officer of Seragon Pharmaceuticals, Inc., a private biotechnology company which was acquired by Genentech in August 2014. Prior to joining Seragon, Dr. Heyman co-founded and served as the chief executive officer of Aragon Pharmaceuticals, Inc. until it was acquired by Johnson & Johnson in August 2013. He is vice chairman of the Board of Trustees at the Salk Institute for Biological Studies, on the Board Foundation for the AACR and on the Board of Visitors at the University of California at San Diego Moores Cancer Center. Dr. Heyman received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut. - Richard Heyman，自2022年12月起担任Rayzebio，Inc.董事会成员和Rayzebio，Inc.董事会主席。Heyman博士是ORIC制药公司、Enliven治疗公司和PMV制药公司的董事会成员。Heyman博士是Metacrine公司的联合创始人，2015年6月至2023年3月担任该公司董事会主席，2015年10月至2016年6月担任该公司临时首席执行官。Heyman博士曾于2015年11月至2022年8月担任生物技术公司Gritstone Oncology的董事会成员，并于2016年5月至2022年6月担任生物技术公司Yumanity的董事会成员。从2013年8月至2015年4月，海曼博士担任私营生物技术公司Seragon Pharmaceuticals，Inc.的首席执行官，该公司于2014年8月被基因泰克收购。在加入Seragon之前，Heyman博士是Aragon Pharmaceuticals，Inc.的联合创始人和首席执行官，直到2013年8月被强生收购。他是索尔克生物研究所董事会副主席，AACR董事会基金会副主席，加州大学圣迭戈摩尔斯癌症中心访客委员会副主席。Heyman博士在明尼苏达大学获得药理学博士学位，在康涅狄格大学获得化学学士学位。
- Richard Heyman,has served as a member of Rayzebio, Inc. board of directors and as Chairman of Rayzebio, Inc. board of directors since December 2022. Dr. Heyman serves as a member of the boards of directors of ORIC Pharmaceuticals, Inc., Enliven Therapeutics, Inc. and PMV Pharmaceuticals, Inc. Dr. Heyman was the co-founder of Metacrine, Inc. and served as the Chairman of its board of directors from June 2015 to March 2023 and was a co-founder of ORIC Pharmaceuticals, Inc. and served as its interim chief executive officer from October 2015 until June 2016. Dr. Heyman previously served as a member of the board of directors of Gritstone Oncology, a biotechnology company, from November 2015 to August 2022 and Yumanity, a biotechnology company, from May 2016 to June 2022. From August 2013 until April 2015, Dr. Heyman served as the chief executive officer of Seragon Pharmaceuticals, Inc., a private biotechnology company which was acquired by Genentech in August 2014. Prior to joining Seragon, Dr. Heyman co-founded and served as the chief executive officer of Aragon Pharmaceuticals, Inc. until it was acquired by Johnson & Johnson in August 2013. He is vice chairman of the Board of Trustees at the Salk Institute for Biological Studies, on the Board Foundation for the AACR and on the Board of Visitors at the University of California at San Diego Moores Cancer Center. Dr. Heyman received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.
- Peter Svennilson
-
Peter Svennilson，曾担任Carmot Therapeutics Inc.的成员。自2020年3月起担任董事会成员。他曾担任风险投资公司the Column Group, LLC(2007年成立以来)的创始人和管理合伙人。Svennilson先生曾担任上市生物制药公司PTC Therapeutics, Inc.(2012年至2014年)、Immune Design Corp.(2014年至2018年)、Gritstone bio, Inc.(2015年9月至2019年9月)和Constellation Pharmaceuticals, Inc.(2016年6月至2019年6月)、Revolution Medicines, Inc.(2020年6月至2021年6月)、ORIC Pharmaceuticals, Inc.(2014年8月至2021年8月)、RAPT Therapeutics, Inc.(2020年4月至2021年6月)的董事会成员。2008年1月至2020年5月担任NGM biopharpharmaceuticals, Inc.的董事。此前，他从2013年起担任Seragon Pharmaceuticals Inc.的董事会主席，直到该公司于2014年被Genentech, Inc.收购。他从2009年起担任Aragon Pharmaceuticals Inc.的董事会主席，直到该公司于2013年被强生公司收购。从1996年到2006年，他是Three Crowns Capital(生物技术风险投资公司)的创始人和管理合伙人。他持有the Stockholm School of Economics and Finance的学士学位和工商管理硕士学位。
Peter Svennilson,has served as a member of Carmot Therapeutics Inc. Board of Directors since March 2020. Mr. Svennilson has served as a founder and managing partner of the venture capital firm, The Column Group, LLC since its inception in 2007. Mr. Svennilson served as a board member of the publicly traded biopharmaceutical companies, PTC Therapeutics, Inc. from 2012 until 2014, Immune Design Corp. from 2014 until 2018, Gritstone bio, Inc. from September 2015 until September 2019 and Constellation Pharmaceuticals, Inc. from June 2016 until June 2019, Revolution Medicines, Inc. from June 2020 to June 2021, ORIC Pharmaceuticals, Inc. from August 2014 to August 2021, RAPT Therapeutics, Inc. from April 2020 to June 2021, and NGM Biopharmaceuticals, Inc. from January 2008 to May 2020. Previously, he served as Chairman of the board of directors of Seragon Pharmaceuticals Inc. from 2013 until it was acquired by Genentech, Inc. in 2014. He was the Chairman of the board of directors of Aragon Pharmaceuticals Inc. from 2009 until it was acquired by Johnson & Johnson in 2013. From 1996 to 2006, he was the founder and managing partner of Three Crowns Capital, a biotechnology venture capital firm. Mr. Svennilson received a B.S. and an M.B.A. from the Stockholm School of Economics and Finance. - Peter Svennilson，曾担任Carmot Therapeutics Inc.的成员。自2020年3月起担任董事会成员。他曾担任风险投资公司the Column Group, LLC(2007年成立以来)的创始人和管理合伙人。Svennilson先生曾担任上市生物制药公司PTC Therapeutics, Inc.(2012年至2014年)、Immune Design Corp.(2014年至2018年)、Gritstone bio, Inc.(2015年9月至2019年9月)和Constellation Pharmaceuticals, Inc.(2016年6月至2019年6月)、Revolution Medicines, Inc.(2020年6月至2021年6月)、ORIC Pharmaceuticals, Inc.(2014年8月至2021年8月)、RAPT Therapeutics, Inc.(2020年4月至2021年6月)的董事会成员。2008年1月至2020年5月担任NGM biopharpharmaceuticals, Inc.的董事。此前，他从2013年起担任Seragon Pharmaceuticals Inc.的董事会主席，直到该公司于2014年被Genentech, Inc.收购。他从2009年起担任Aragon Pharmaceuticals Inc.的董事会主席，直到该公司于2013年被强生公司收购。从1996年到2006年，他是Three Crowns Capital(生物技术风险投资公司)的创始人和管理合伙人。他持有the Stockholm School of Economics and Finance的学士学位和工商管理硕士学位。
- Peter Svennilson,has served as a member of Carmot Therapeutics Inc. Board of Directors since March 2020. Mr. Svennilson has served as a founder and managing partner of the venture capital firm, The Column Group, LLC since its inception in 2007. Mr. Svennilson served as a board member of the publicly traded biopharmaceutical companies, PTC Therapeutics, Inc. from 2012 until 2014, Immune Design Corp. from 2014 until 2018, Gritstone bio, Inc. from September 2015 until September 2019 and Constellation Pharmaceuticals, Inc. from June 2016 until June 2019, Revolution Medicines, Inc. from June 2020 to June 2021, ORIC Pharmaceuticals, Inc. from August 2014 to August 2021, RAPT Therapeutics, Inc. from April 2020 to June 2021, and NGM Biopharmaceuticals, Inc. from January 2008 to May 2020. Previously, he served as Chairman of the board of directors of Seragon Pharmaceuticals Inc. from 2013 until it was acquired by Genentech, Inc. in 2014. He was the Chairman of the board of directors of Aragon Pharmaceuticals Inc. from 2009 until it was acquired by Johnson & Johnson in 2013. From 1996 to 2006, he was the founder and managing partner of Three Crowns Capital, a biotechnology venture capital firm. Mr. Svennilson received a B.S. and an M.B.A. from the Stockholm School of Economics and Finance.
高管简历
中英对照 | 中文 | 英文- Pratik Multani
Pratik Multani ，2015年2月加入我们并担任首席医疗官。此前，2009年4月-2015年1月，在Fate Therapeutics, Inc.担任首席医疗官。此前，2007-2009年3月，在Kalypsys, Inc. 担任临床发展副总裁。2005-2007，担任Kanisa Pharmaceuticals, Inc. 临床发展高级副总裁，随后担任首席医疗官；1999-2004，担任Biogen-Idec的肿瘤学和血液学副主任和医学研究高级主任。持有Harvard 公共卫生学院的流行病学硕士学位、Harvard 医学院的医学博士学位和Yale 大学的化学和生物学学士学位。他在 Massachusetts General Hospital完成了他的内科住院医师；随后在Dana Farber/Partners联合方案的医学肿瘤学奖学金学习；此前是Massachusetts General Hospital的移植单位成员。
Pratik Multani has served as our Chief Medical Officer since September 2018. From February 2015 to February 2018 he served as the Chief Medical Officer of Ignyta, that was acquired by Roche in February 2018. From April 2009 to January 2015 Dr. Multani was Chief Medical Officer at Fate Therapeutics, Inc., a biopharmaceutical company. Prior to that, Dr. Multani was Vice President of Clinical Development at Kalypsys, Inc. and Senior Vice President of Clinical Development and Chief Medical Officer at Kanisa Pharmaceuticals, Inc. He currently serves on the board of directors of Chimerix, Inc., a biopharmaceutical company. Dr. Multani received an M.D. from Harvard Medical School, an M.S. in epidemiology from Harvard School of Public Health and a B.S. in chemistry and biology from Yale University.- Pratik Multani ，2015年2月加入我们并担任首席医疗官。此前，2009年4月-2015年1月，在Fate Therapeutics, Inc.担任首席医疗官。此前，2007-2009年3月，在Kalypsys, Inc. 担任临床发展副总裁。2005-2007，担任Kanisa Pharmaceuticals, Inc. 临床发展高级副总裁，随后担任首席医疗官；1999-2004，担任Biogen-Idec的肿瘤学和血液学副主任和医学研究高级主任。持有Harvard 公共卫生学院的流行病学硕士学位、Harvard 医学院的医学博士学位和Yale 大学的化学和生物学学士学位。他在 Massachusetts General Hospital完成了他的内科住院医师；随后在Dana Farber/Partners联合方案的医学肿瘤学奖学金学习；此前是Massachusetts General Hospital的移植单位成员。
- Pratik Multani has served as our Chief Medical Officer since September 2018. From February 2015 to February 2018 he served as the Chief Medical Officer of Ignyta, that was acquired by Roche in February 2018. From April 2009 to January 2015 Dr. Multani was Chief Medical Officer at Fate Therapeutics, Inc., a biopharmaceutical company. Prior to that, Dr. Multani was Vice President of Clinical Development at Kalypsys, Inc. and Senior Vice President of Clinical Development and Chief Medical Officer at Kanisa Pharmaceuticals, Inc. He currently serves on the board of directors of Chimerix, Inc., a biopharmaceutical company. Dr. Multani received an M.D. from Harvard Medical School, an M.S. in epidemiology from Harvard School of Public Health and a B.S. in chemistry and biology from Yale University.
- Jacob M. Chacko
JacobM.Chacko自2018年5月起担任我们的首席执行官兼董事会成员，自2019年5月起担任我们的总裁。2014年5月至2018年2月，他担任精密肿瘤公司Ignyta，Inc.的首席财务官，该公司于2018年2月被制药和诊断公司Roche Holding AG收购。2008年8月至2014年5月，Chacko博士担任私募股权投资公司TPG Capital的Vice President。在此之前，Chacko博士是麦肯锡公司（McKinsey&Company）梦百合客户的顾问，这是一家管理咨询公司。他目前任职于制药公司Turning PointTherapeutics，Inc.和制药公司4DMolecularTherapeutics，Inc.的董事会。Chacko博士在加州大学洛杉矶分校（UCLA）获得工商管理硕士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。从牛津大学获得生物学学士学位，从南加州大学获得老年学学士学位。
Jacob M. Chacko has served as our Chief Executive Officer and as a member of our board of directors since May 2018 and as our President since May 2019. From May 2014 to February 2018 he served as Chief Financial Officer of Ignyta, Inc., a precision oncology company that was acquired in February 2018 by Roche Holding AG, a pharmaceuticals and diagnostics company. From August 2008 to May 2014 Dr. Chacko served as Vice President at TPG Capital, a private equity investment firm. Prior to that, Dr. Chacko was a consultant to healthcare clients at McKinsey & Company, a management consulting firm. He currently serves on the board of directors of Turning Point Therapeutics, Inc., a pharmaceutical company, and 4D Molecular Therapeutics, Inc., a pharmaceutical company. Dr. Chacko received an M.D. from UCLA, an M.B.A. from Harvard Business School, an M.Sc. from Oxford University and a B.A. in biology and B.S. in gerontology from the University of Southern California.- JacobM.Chacko自2018年5月起担任我们的首席执行官兼董事会成员，自2019年5月起担任我们的总裁。2014年5月至2018年2月，他担任精密肿瘤公司Ignyta，Inc.的首席财务官，该公司于2018年2月被制药和诊断公司Roche Holding AG收购。2008年8月至2014年5月，Chacko博士担任私募股权投资公司TPG Capital的Vice President。在此之前，Chacko博士是麦肯锡公司（McKinsey&Company）梦百合客户的顾问，这是一家管理咨询公司。他目前任职于制药公司Turning PointTherapeutics，Inc.和制药公司4DMolecularTherapeutics，Inc.的董事会。Chacko博士在加州大学洛杉矶分校（UCLA）获得工商管理硕士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。从牛津大学获得生物学学士学位，从南加州大学获得老年学学士学位。
- Jacob M. Chacko has served as our Chief Executive Officer and as a member of our board of directors since May 2018 and as our President since May 2019. From May 2014 to February 2018 he served as Chief Financial Officer of Ignyta, Inc., a precision oncology company that was acquired in February 2018 by Roche Holding AG, a pharmaceuticals and diagnostics company. From August 2008 to May 2014 Dr. Chacko served as Vice President at TPG Capital, a private equity investment firm. Prior to that, Dr. Chacko was a consultant to healthcare clients at McKinsey & Company, a management consulting firm. He currently serves on the board of directors of Turning Point Therapeutics, Inc., a pharmaceutical company, and 4D Molecular Therapeutics, Inc., a pharmaceutical company. Dr. Chacko received an M.D. from UCLA, an M.B.A. from Harvard Business School, an M.Sc. from Oxford University and a B.A. in biology and B.S. in gerontology from the University of Southern California.
- Dominic Piscitelli
Dominic Piscitelli自2019年9月起担任我们的首席财务官。2017年1月至2019年9月，他担任生物技术公司AnaptysBio，Inc.的首席财务官。从2012年9月至2017年1月，皮斯切利先生担任生物制药公司Medivation，Inc.的财务Vice President。在此之前，Piscitelli先生在Astellas Pharma US（一家制药公司）和OSI Pharmaceuticals，Inc.（一家被Astellas Pharma US收购的制药公司）担任多个职位。Piscitelli先生在霍夫斯特拉大学（Hofstra University）获得会计学和金融学的工商管理硕士学位和学士学位。
Dominic Piscitelli has served as our Chief Financial Officer since September 2019. From January 2017 to September 2019 he served as Chief Financial Officer of AnaptysBio, Inc., a biotechnology company. From September 2012 to January 2017 Mr. Piscitelli served as the Vice President of Finance at Medivation, Inc., a biopharmaceutical company. Prior to that, Mr. Piscitelli held various positions at Astellas Pharma US, a pharmaceutical company, and OSI Pharmaceuticals, Inc., a pharmaceutical company acquired by Astellas Pharma US. Mr. Piscitelli received an M.B.A. and B.S. in accounting and finance from Hofstra University.- Dominic Piscitelli自2019年9月起担任我们的首席财务官。2017年1月至2019年9月，他担任生物技术公司AnaptysBio，Inc.的首席财务官。从2012年9月至2017年1月，皮斯切利先生担任生物制药公司Medivation，Inc.的财务Vice President。在此之前，Piscitelli先生在Astellas Pharma US（一家制药公司）和OSI Pharmaceuticals，Inc.（一家被Astellas Pharma US收购的制药公司）担任多个职位。Piscitelli先生在霍夫斯特拉大学（Hofstra University）获得会计学和金融学的工商管理硕士学位和学士学位。
- Dominic Piscitelli has served as our Chief Financial Officer since September 2019. From January 2017 to September 2019 he served as Chief Financial Officer of AnaptysBio, Inc., a biotechnology company. From September 2012 to January 2017 Mr. Piscitelli served as the Vice President of Finance at Medivation, Inc., a biopharmaceutical company. Prior to that, Mr. Piscitelli held various positions at Astellas Pharma US, a pharmaceutical company, and OSI Pharmaceuticals, Inc., a pharmaceutical company acquired by Astellas Pharma US. Mr. Piscitelli received an M.B.A. and B.S. in accounting and finance from Hofstra University.